{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:31:43Z","timestamp":1793291503375,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ghir.2017.08.001","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T01:33:10Z","timestamp":1502760790000},"page":"11-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR)"],"prefix":"10.1016","volume":"36","author":[{"given":"Anya","family":"Rothenbuhler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Esterle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Gueorguieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Mignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Colle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ghir.2017.08.001_bb0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/ndt\/14.2.333","article-title":"X-linked hypophosphataemia: a homologous disorder in humans and mice","volume":"14","author":"Tenenhouse","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ghir.2017.08.001_bb0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ghir.2017.08.001_bb0015","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2005111185","article-title":"Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D","volume":"17","author":"Liu","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ghir.2017.08.001_bb0020","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ghir.2017.08.001_bb0025","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/ki.1996.149","article-title":"Renal Na(+)-phosphate cotransporter gene expression in X-linked Hyp and Gy mice","volume":"49","author":"Tenenhouse","year":"1996","journal-title":"Kidney Int."},{"key":"10.1016\/j.ghir.2017.08.001_bb0030","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ghir.2017.08.001_bb0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1302\/0301-620X.93B1.24788","article-title":"Combined technique for the correction of lower-limb deformities resulting from metabolic bone disease","volume":"93","author":"Kocaoglu","year":"2011","journal-title":"J. Bone Joint Surg. (Br.)"},{"key":"10.1016\/j.ghir.2017.08.001_bb0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11154-008-9075-3","article-title":"Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation","volume":"9","author":"Bastepe","year":"2008","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.ghir.2017.08.001_bb0045","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00431-007-0662-1","article-title":"What's new in hypophosphataemic rickets?","volume":"167","author":"Pettifor","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ghir.2017.08.001_bb0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00431-006-0357-z","article-title":"Growth in X-linked hypophosphatemic rickets","volume":"166","author":"Ariceta","year":"2007","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ghir.2017.08.001_bb0055","first-page":"33","article-title":"Clinical course of hypophosphatemic rickets in 23 adults","volume":"45","author":"Berndt","year":"1996","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ghir.2017.08.001_bb0060","first-page":"839","article-title":"Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia","volume":"76","author":"Friedman","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.08.001_bb0065","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM198010303031802","article-title":"Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets","volume":"303","author":"Glorieux","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ghir.2017.08.001_bb0070","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1542\/peds.113.6.e593","article-title":"Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets","volume":"113","author":"Haffner","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.ghir.2017.08.001_bb0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000045518","article-title":"Long-term outcome of paediatric patients with hereditary tubular disorders","volume":"83","author":"Haffner","year":"1999","journal-title":"Nephron"},{"key":"10.1016\/j.ghir.2017.08.001_bb0080","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1210\/jc.2007-2553","article-title":"Vitamin D receptor genotype in hypophosphatemic rickets as a predictor of growth and response to treatment","volume":"93","author":"Jehan","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.08.001_bb0085","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.ghir.2017.08.001_bb0090","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/BF01959355","article-title":"The pattern of growth and growth retardation of patients with hypophosphataemic vitamin D-resistant rickets: a longitudinal study","volume":"151","author":"Steendijk","year":"1992","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ghir.2017.08.001_bb0095","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","article-title":"Effects of therapy in X-linked hypophosphatemic rickets","volume":"325","author":"Verge","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ghir.2017.08.001_bb0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00467-010-1705-9","article-title":"Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets","volume":"26","author":"Zivicnjak","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ghir.2017.08.001_bb0105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1067\/mpd.2001.108955","article-title":"Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets","volume":"138","author":"Baroncelli","year":"2001","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ghir.2017.08.001_bb0110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/BF02079060","article-title":"Disproportionate growth following long-term growth hormone treatment in short children with X-linked hypophosphataemia","volume":"154","author":"Haffner","year":"1995","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ghir.2017.08.001_bb0115","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s004670050340","article-title":"X-linked hypophosphatemia: effects of treatment with recombinant human growth hormone","volume":"11","author":"Reusz","year":"1997","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ghir.2017.08.001_bb0120","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0022-3476(95)70070-6","article-title":"Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density","volume":"127","author":"Saggese","year":"1995","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ghir.2017.08.001_bb0125","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1542\/peds.100.5.879","article-title":"The effect of recombinant human growth hormone in children with X-linked hypophosphatemia","volume":"100","author":"Seikaly","year":"1997","journal-title":"Pediatrics"},{"key":"10.1016\/j.ghir.2017.08.001_bb0130","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1210\/jc.2009-2531","article-title":"Near normalization of adult height and body proportions by growth hormone in pycnodysostosis","volume":"95","author":"Rothenbuhler","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.08.001_bb0135","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1210\/jc.2008-0509","article-title":"Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop","volume":"93","author":"Cohen","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.08.001_bb0140","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1210\/jc.2009-2139","article-title":"Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children","volume":"95","author":"Cohen","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.08.001_bb0145","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1210\/jc.2007-0204","article-title":"Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study","volume":"92","author":"Cohen","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637417300709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637417300709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:49:53Z","timestamp":1761086993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637417300709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":29,"alternative-id":["S1096637417300709"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2017.08.001","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR)","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2017.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}